Elucid, a medical technology company specializing in AI-powered imaging analysis software for cardiovascular disease assessment, raises $80 million in Series C funding led by Elevage Medical Technologies. Elucid’s FDA-cleared software offers non-invasive, histologically accurate arterial plaque characterization, providing a valuable diagnostic tool. The funding will support commercialization efforts and advance Elucid’s mission to enhance cardiovascular disease diagnosis and treatment, potentially reducing heart attack and stroke fatalities. The investment includes participation from industry strategics and existing investors, facilitating further development.
What You Should Know:
– Elucid, a medical technology company providing AI-powered imaging analysis software to assess cardiovascular disease, has raised $80M in Series C funding led by Elevage Medical Technologies, with additional participation from industry strategics and existing investors.
– This funding will enable Elucid to expand its commercialization efforts, providing physicians and patients with AI-powered imaging analysis software to assess and combat cardiovascular disease.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
AI-powered Cardiovascular Diagnostic Tools
Cardiovascular disease is the leading global cause of death and disability, primarily driven by conditions such as myocardial infarction and ischemic stroke due to atherosclerosis. Elucid’s software is the only FDA-cleared non-invasive tool able to accurately characterize arterial plaque, simulating what pathologists would see under a microscope. Elucid’s technology addresses the need for more objective and non-invasive diagnostic methods to accurately quantify and characterize arterial plaque, offering a histologic ground truth for plaque assessment.
The company is also pursuing an indication for non-invasive measurement of fractional flow reserve (FFRCT), uniquely derived from its PlaqueIQ technology, to measure coronary blockages and the extent of ischemia. The funding and partnership with Elevage Medical will help Elucid advance its mission to improve cardiovascular disease diagnosis and treatment, ultimately reducing heart attack and stroke deaths.
Dr. Evan Melrose, CEO of Elevage, and Dr. Kelly Huang will join Elucid’s board of directors. Scott Huennekens was named executive chairman of the board, and Elucid has strengthened its leadership team with key appointments in various roles.
